PULSAR LIFE SCIENCES, INC.

Medtech · Private

Small-molecule CaMKK2 inhibitors for topical ocular treatment of graft versus host disease and ocular surface inflammatory diseases

Grants
$1.5M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Novel Small Molecule Anti-Inflammatory Eye Drops for Ocular Graft Versus Host Disease$749,999
Federal grantDepartment of Health and Human Services · Phase II · Novel Small Molecule Anti-Inflammatory Eye Drops for Ocular Graft Versus Host Disease$750,000
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
727CuRE Innovations, LLC——
728FLOBIO LLC——
729Onda Vision Technologies, LLC——
730PULSAR LIFE SCIENCES, INC.——
731INTUOR TECHNOLOGIES LLC——
732NEUROTARGETING SYSTEMS——
733Global Innovative Platforms Inc.—$470K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.